PRAX

Business Context and Reporting Period

This Form 8-K reports on the Special Meeting of Stockholders held by Praxis Precision Medicines, Inc. on November 6, 2023. The meeting was convened to vote on proposals regarding corporate governance and capital structure adjustments.

Key Financial Metrics

This filing is a current report regarding stockholder voting results and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.

Material Changes and Voting Results

Stockholders approved two key proposals at the Special Meeting:

• Proposal 1 (Reverse Stock Split): Approved amendments to the Certificate of Incorporation granting the Board discretionary authority to effect a reverse stock split of common stock at a ratio between 1-for-5 and 1-for-25.
• Proposal 2 (Adjournment): Approved the authority to adjourn the meeting to solicit further proxies if necessary to secure approval for the Reverse Stock Split Proposal.

Voting Breakdown for Proposal 1:

Voting Breakdown for Proposal 2:

Guidance, Outlook, and Risks

The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the context of the stock split authorization. The primary strategic implication is the Board's new ability to adjust the share count to potentially maintain compliance with Nasdaq listing requirements.

Investor Verification Checklist

• Verify the specific reverse stock split ratio and implementation date once announced by the Board.
• Review the Definitive Proxy Statement (Schedule 14A) filed on October 16, 2023, for detailed rationale behind the proposals.
• Monitor subsequent filings for the actual execution of the reverse stock split.
• Check current Nasdaq listing compliance status relative to the company's share price and volume.